Nobuhiro Hattori
Osaka University of Pharmaceutical Sciences(JP)
Publications by Year
Research Areas
Gallbladder and Bile Duct Disorders, Pancreatic and Hepatic Oncology Research, Hepatocellular Carcinoma Treatment and Prognosis, Pediatric Hepatobiliary Diseases and Treatments, Cholangiocarcinoma and Gallbladder Cancer Studies
Most-Cited Works
- → Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated with Lenvatinib(2019)89 cited
- → L-carnitine Reduces Muscle Cramps in Patients With Cirrhosis(2014)72 cited
- → Wisteria floribunda agglutinin positive human Mac‐2‐binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients(2015)63 cited
- → <p>Safety and Efficacy of Lenvatinib Treatment in Child–Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis</p>(2020)53 cited
- → Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma(2020)52 cited
- → Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis(2021)50 cited
- → Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis(2020)38 cited
- → Naturally occurring, resistance‐associated hepatitis C virus NS5A variants are linked to interleukin‐28B genotype and are sensitive to interferon‐based therapy(2015)38 cited
- → Correlations of Hepatic Hemodynamics, Liver Function, and Fibrosis Markers in Nonalcoholic Fatty Liver Disease: Comparison with Chronic Hepatitis Related to Hepatitis C Virus(2016)31 cited
- → Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema(2019)23 cited